Effect of a Ketohexokinase Inhibitor (PF‐06835919) on <i>In Vivo</i> OATP1B Activity: Integrative Risk Assessment Using Endogenous Biomarker and a Probe Drug-Reference-Cited by-同舟云学术

Effect of a Ketohexokinase Inhibitor (PF‐06835919) on In Vivo OATP1B Activity: Integrative Risk Assessment Using Endogenous Biomarker and a Probe Drug

Published:2022-05-09 Issue:3 Volume:112 Page:605-614
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:en
Short-container-title:Clin Pharma and Therapeutics

Author:

Tess David A.¹,Kimoto Emi²,King‐Ahmad Amanda²,Vourvahis Manoli³,Rodrigues A. David²,Bergman Arthur⁴,Qui Ruolun⁴,Somayaji Veena⁵,Weng Yan⁴,Fonseca Kari R.¹,Litchfield John¹,Varma Manthena V. S.²

Affiliation:

1. Pharmacokinetics, Dynamics and Metabolism, Medicine Design Worldwide Research & Development Pfizer Inc Cambridge Massachusetts USA

2. Pharmacokinetics, Dynamics and Metabolism, Medicine Design Worldwide Research & Development Pfizer Inc. Groton Connecticut USA

3. Clinical Pharmacology Global Product Development Pfizer Inc New York New York USA

4. Clinical Pharmacology Early Clinical Development Pfizer Inc. Cambridge Massachusetts USA

5. Clinical Biostatistics Early Clinical Development Pfizer Inc Cambridge Massachusetts USA

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpt.2593

Reference37 articles.

1. The metabolism of fructose in liver. Isolation of fructose-1-phosphate and inorganic pyrophosphate

2. Opposing effects of fructokinase C and A isoforms on fructose-induced metabolic syndrome in mice

3. High-fat and high-sucrose (western) diet induces steatohepatitis that is dependent on fructokinase

4. Discovery of PF-06835919: A Potent Inhibitor of Ketohexokinase (KHK) for the Treatment of Metabolic Disorders Driven by the Overconsumption of Fructose

5. Pharmacologic inhibition of ketohexokinase prevents fructose-induced metabolic dysfunction

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Membrane transporters in drug development and as determinants of precision medicine;Nature Reviews Drug Discovery;2024-01-24

2. Utilization of OATP1B Biomarker Coproporphyrin‐I to Guide Drug–Drug Interaction Risk Assessment: Evaluation by the Pharmaceutical Industry;Clinical Pharmacology & Therapeutics;2023-10-11

3. Utility of Coproporphyrin-I Determination in First-in-Human Study for Early Evaluation of OATP1B Inhibitory Potential Based on Investigation of Ensitrelvir, an Oral SARS-CoV-2 3C-Like Protease Inhibitor;Journal of Pharmaceutical Sciences;2023-09

4. The Role of Coproporphyrins As Endogenous Biomarkers for Organic Anion Transporting Polypeptide 1B Inhibition–Progress from 2016 to 2023;Drug Metabolism and Disposition;2023-07-05

5. Progress in the Quantitative Assessment of Transporter-Mediated Drug–Drug Interactions Using Endogenous Substrates in Clinical Studies;Drug Metabolism and Disposition;2023-05-11